

# Kangaroo Care with Father's protocol: an intervention to reduce pain response in preterm neonates (28 - 36 weeks gestation)

<b>Submission date</b> 16/02/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 31/03/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 02/11/2011	<b>Condition category</b> Signs and Symptoms	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Celeste Johnston

### Contact details

3506 University, room 226

Montreal, QC

H3A 2A7

Montreal

Canada

H3A 2A7

+1 514 398 4157

celeste.johnston@mcgill.ca

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

## Study information

### Scientific Title

Kangaroo Care with Father's protocol: an intervention to reduce pain response in preterm neonates (28 - 36 weeks gestation): a randomised controlled crossover trial

### Acronym

FKC

### Study objectives

There will be a difference in pain response, time to recovery and heart rate variability (HRV) from heel lance in 28 - 36 weeks gestational age Neonatal Intensive Care Unit (NICU) preterm neonates when they are engaged in maternal kangaroo care (KC) compared to when they are engaged in father's KC.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

CHU St-Justine Research Ethics Board (REB) gave approval on the 16th July 2007 (ref: 2580)

### Study design

Randomised controlled crossover trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Pain response during heel lancing

### Interventions

After obtained informed consent from the mother and the father, the neonate will be randomised to intervention (father first mother second) or control (mother first father second). Kangaroo care involves placing a diaper-clad neonate at an angle of sixty degrees between the breasts or on the chest providing maximal skin-to-skin contact between the infant and the

caregiver. The neonate is placed in KC 15 minutes before the painful procedure (heel lance) performed by a hospital technician assigned to the study. The heel lance procedure is relatively standardised across staff and timing and is an aspect of routine care for hospitalised preterm neonates. Each neonate will have two KC sessions filmed; one with the mother and the other one with the father. The measures will be taken for the entire heel lance procedure (one minute of baseline isolette, one minute of baseline kangaroo, one minute of warming, extraction of the blood and return to baseline kangaroo and isolette).

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome measure**

1. Pain measured with Premature Infant Pain Profile (PIPP), repeated over 30 second blocks
2. Facial actions of the PIPP scored according to Neonatal Facial Coding System (NFCS)

**Secondary outcome measures**

Timing for return to physiologic baseline measured as the preterm neonate's return to baseline HR after the heel lance procedure procured via an oximeter placed on the unaffected foot of the neonate.

**Overall study start date**

01/10/2007

**Completion date**

01/04/2009

## Eligibility

**Key inclusion criteria**

1. Born between 28 0/7 and 35 6/7 weeks of gestation, either sex
2. Obtained consent
3. Receiving at least two heel lances prior to discharge
4. Within 10 days of hospitalisation
5. Stable according to Neonatal Intensive Care Unit criteria

**Participant type(s)**

Patient

**Age group**

Neonate

**Sex**

Both

**Target number of participants**

80

**Key exclusion criteria**

1. Genetic or major congenital disorders
2. Requiring surgery before or during the study period
3. Receiving analgesics or paralysing agents
4. Intra-ventricular haemorrhage (IVH) grade III+ or periventricular leukomalacia (PVL) as confirmed by ultrasound

**Date of first enrolment**

01/10/2007

**Date of final enrolment**

01/04/2009

**Locations****Countries of recruitment**

Canada

**Study participating centre**

3506 University, room 226

Montreal

Canada

H3A 2A7

**Sponsor information****Organisation**

McGill University (Canada)

**Sponsor details**

c/o Dr Celeste Johnston

School of Nursing

3506 University, Room 226

Montreal

Canada

H3A 2A7

+1 514 398 4157

celeste.johnston@mcgill.ca

**Sponsor type**

University/education

**Website**

<http://www.mcgill.ca>

ROR

<https://ror.org/01pxwe438>

## Funder(s)

### Funder type

Research organisation

### Funder Name

Canadian Institutes of Health Research (Canada) - <http://www.cihr-irsc.gc.ca> (ref: MOP-64307)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2011		Yes	No